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Along the last years it has been demonstrated that non-neural cells play a major
role in the pathogenesis of the primary degenerative disorders (PDDs) of the human
central nervous system. Among them, astrocytes coordinate and participate in many
different and complex metabolic processes, in close interaction with neurons. Moreover,
increasing experimental evidence hints an early astrocytic dysfunction in these diseases.
In this mini review we summarize the astrocytic behavior in PDDs, with special
consideration to the experimental observations where astrocytic pathology precedes the
development of neuronal dysfunction. We also suggest a different approach that could
be consider in human investigations in Alzheimer’s and Parkinson’s disease. We believe
that the study of PDDs with human brain samples may hold the key of a paradigmatic
physiopathological process in which astrocytes might be the main players.
Keywords: astrocytes, primary degenerative disorders, human central nervous system, neurodegeneration,
primary astrocytic degeneration
FIRST STEPS: NEURODEGENERATION
Since the beginning of the 20th century relentlessly progressive neurological diseases have
classically been attributed to a primary neuronal dysfunction. This affirmation applies to Parkinson
disease (PD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD), among others (Pendlebury et al., 1987; Manetto et al., 1988). Therefore,
most investigations have been carried out under this belief, leading to the coining of the
term “neurodegeneration.” This paradigm was later on applied to psychiatric diseases such as
Schizophrenia and Major depression (Harrison, 1999; Delgado, 2004). As a result of those efforts,
a detailed description of neurons’ characteristics in the main affected areas in those diseases as
well as a broadening of the knowledge of neuronal functioning was achieved. Since then, several
physiopathological hypotheses were constructed; notwithstanding that when put into practice
by therapeutical testing, results have not met the expectations (McDermott and Rowland, 2001;
Broadstock et al., 2014).
In the 90s, a new era began that considered the possibility of a more important role of the so
far neglected neuroglia. This led to different findings opposed to the belief of the astrocytes sole
function being neuronal structural support.
Astrocytes have been found to have a much more active role that the one predicted by the earlier
guessers. Particularly, they are involved in the ions exchange with neurons, they are organized as a
syncytium that allows them to interchange information with other astrocytes residing in a defined
net through different types of Ca+++ signals while regulating the release of signaling molecules
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involved in the production of trophic factors, transmitters and
transporters that when released to the extracellular medium
will modulate the synaptic activity synchronizing the neuronal
functions. Also they are involved in the extracellular K+ uptake,
in synaptogenesis and gene expression; adapting, at the same
time, the permeability of the blood–brain barrier to the neuronal
and synaptic needs (Reichenbach et al., 2010; Gordon et al., 2011;
Rash et al., 2012; Khakh and Sofroniew, 2015). A more exhaustive
description of the astrocytes properties and functions is beyond
the scope of this mini review and is detailed elsewhere (Sica,
2015).
THE NEW ERA: PRIMARY
DEGENERATIVE DISORDERS
Slowly but relentlessly, the results of several studies confirmed
the existence of an active role played not only by the astrocytes
but also by microglia. Mounting evidence suggests that astrocytes
modulate microglial response, through the establishment of a
complex cross-talk between both types of cells mediated by the
production of different chemokines and cytokines (Cudaback
et al., 2015; Rothhammer and Quintana, 2015). Therefore, we
think that the broader term primary degenerative disorders of
the central nervous system (PDD CNS) alludes to the complex
pathology of these diseases (in contrast to the classic term
neurodegeneration) and will be used henceforward in this article.
Astrocytic findings in the PDDs include:
In FTD, the classic approach subdivided the frontotemporal
anatomic atrophy with regards to the concomitant
histopathological findings, that is: Pick disease when tau-positive
intraneuronal inclusions were found, FTD with motor neuron
disease when tau-negative-ubiquitine-positive intracellular
inclusions were present in motor neurons or Frontotemporal
Lobar Degeneration when no particular histopathological
features were observed (Broe et al., 2004). On the contrary,
recent studies have demonstrated that regardless of the presence
or absence of the “classic” neuronal inclusions, clinical disease
progression is associated with the extent of neuronal loss, the
degree of extracellular microvacuolation and, regarding glial
pathology, the level of both astrogliosis and astrocytic apoptosis
(Broe et al., 2004; Kersaitis et al., 2004).
With regards to PD, microgliosis has been found in a sustained
fashion by different authors associated with the creation and
maintenance of a vigorous inflammatory state at the substantia
nigra pars compacta (McGeer and McGeer, 2008; McGann et al.,
2012) and striatum, the latter of a strikingly similar characteristics
in animal models and human brain samples (Charron et al.,
2014). The mentioned state seems to be modulated by astrocytes,
through the exocytosis of paracrine factors in the substantia nigra
such as ICAM-1 and IL-6, which in turn act as stimulators of
microglia migration (McGeer and McGeer, 2008).
Regarding AD, in a triple transgenic mouse model it has been
shown that the presence of senile plaques in the hippocampus
induces a mild astrocytic (and microglial) reaction within the
Aβ plaques’ periphery (Olabarria et al., 2010); a finding that
was not observed in the entorhinal or prefrontal cortex (Yeh
et al., 2011; Kulijewicz-Nawrot et al., 2012). However, in human
brain samples astroglial reaction, although present and with a
clear hippocampal preference, seems to be less clearly associated
with amyloid deposition at least in the lateral temporal cortex
(Wharton et al., 2009; Olabarria et al., 2010; Simpson et al., 2010;
Verkhratsky et al., 2010, 2014a; Yeh et al., 2011; Prokop et al.,
2013).
Both in Major Depression and Schizophrenia there seems
to be a mild astrocytic atrophy (characterized mainly by a
decreased expression of GFAP) without a definitive consensus
in relation to the stability of the total number of astrocytes
(Verkhratsky et al., 2014b; Verkhratsky and Parpura, 2015).
Moreover, in Schizoprhenia, several functional astrocytic changes
have been described such as a diminished expression of EAAT1
and EAAT1 (human glutamate transporters) in the prefrontal
cortex, augmented synthesis of condroitin sulfate proteoglycans
in the amygdala and entorhinal cortex, altered metabolism of
D-serine, elevated levels of kynurenic acid (NMDA inhibitor
synthesized by astrocytes), etc. (Rajkowska and Miguel-Hidalgo,
2007; Alexander et al., 2012; Feresten et al., 2013; Verkhratsky
et al., 2014b; Verkhratsky and Parpura, 2015).
Finally, in ALS, astrogliosis both in white and gray matter
is a very important hallmark of the illness all along its course
(Yamanaka et al., 2008; Lasiene and Yamanaka, 2011; Sica, 2012).
In the SOD1G93A transgenic mouse model astroglial atrophy has
been described restricted to the astrocytes associated with the
affected motor neurons (Rossi et al., 2008). Microglia activation
is also increased in ALS and in another SOD1 mouse model
Yamanaka et al. (2008) demonstrated that it could be modulated
by the manipulation of astrocytic behavior (Yamanaka et al., 2008;
Lasiene and Yamanaka, 2011; Sica, 2012).
Special Consideration
A particular difficulty in the study of these diseases is that they
mostly represent a deterioration of a highly evolved cognitive
and/or motor functioning system. Therefore, and punctually
in psychiatric illnesses, it seems that animal models are far
from resembling all the peculiarities of the human diseases,
even if the anatomopathological findings can be mimicked.
On the other hand, human testing is ethically inappropriate
for obvious reasons and therefore, the most representative
research tool available is the study of post mortem human brains
(Harrison, 1999; Broadstock et al., 2014). Furthermore, since
clinical diagnosis relies in a constellation of signs and symptoms
that are secondary to a physiopathogenic process that is far from
recently starting, the study of the disease early-stages is extremely
difficult. All the above determines hazards to the methodological
study approach of many hypotheses, particularly those involving
disease onset and progression.
TEMPORALITY CLUES
We reviewed the international literature in order to find
descriptions in human or animal models which may support the
hypothesis that astrocyte pathology precedes neuronal damage
(Table 1).
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TABLE 1 | Experimental findings suggestive of primary astrocytic damage.
Disease Reference Species Findings
FTD Broe et al., 2004 Human Astrocytic apoptosis is present at early stages and increases
with disease progression.
Kersaitis et al., 2004 Human Astrogliosis is present at early stages of the disease.
PD Halliday and Stevens, 2011 Mice Astrocytic cytoplasmatic α-synuclein deposition precedes
neuronal damage.
AD Olabarria et al., 2010 Mice (3xTg) Hippocampal astroglia atrophy (6th month) precedes the
extracellular Aβ deposition (12th month).
Yeh et al., 2011 Mice (3xTg) Entorhinal astroglial atrophy (1st month) precedes
neurodegeneration (12 months of age).
Kulijewicz-Nawrot et al., 2012 Mice (3xTg) Medial prefrontal astroglial atrophy (1 month of age) precedes
neurodegeneration (12 months of age).
AND Rama Rao and Norenberg, 2014 Mice Hepatic encephalopathy: selective astrocyte swelling.
Hazell, 2009 Human Rats Wernicke’s encephalopathy: loss of EAAT1 and EAAT2
astrocytic glutamate transporters.
ALS Bruijn et al., 1997 Mice (SOD1G85R) SOD1 astrocyte inclusions precede similar neuronal inclusions
and later clinical signs.
Rossi et al., 2008 Mice (SOD1G93A) Abnormal spheroid-shaped astrocytes (75th day) in the ventral
horns of the lumbar spinal cord, astrogliosis of the ventral and
dorsal horns before clinical sings and evident neuron number
reduction (100th day).
Papadeas et al., 2011 Rats (SOD1G93A) Selective astrocytic mutation of SOD1G93A leads to ALS signs.
Tong et al., 2013 Rats Selective astrocytic mutation of Tar DNA-binding protein 43
(TDP-43) leads to ALS signs.
SCA Custer et al., 2006 Mice Bergman glia expressing ataxin-7 lead to SCA symptoms.
HD Faideau et al., 2010 Mice Human Selective expression of mutant Huntingtin in mice astrocytes
leads to HD signs.
Astrogliosis in the dorsal stratum in two human brain samples
without clinical symptoms (grade 0).
Bradford et al., 2009 Mice Selective expression of mutant Huntingtin in mice astrocytes
leads to HD signs.
FTD, Frontotemporal dementia; PD, Parkinson disease; AD, Alzheimer’s disease; AND, Acquired neuropsychiatric disease; ALS, Amyotrophic lateral sclerosis; SCA,
Spinocerebellar ataxia; HD, Huntington disease.
Human anatomical material is scarce regarding this point
because cadaveric material, such as brains and spinal cords,
belongs mostly to patients who at the time of their death were
already at late stages of their pathological process.
However, there are some observations in animal
experimentation, which situates astrocytic damage at the
beginning of the pathological timeline. Examples are as follows:
Frontotemporal Dementia
In recent human studies astrocytes showing apoptotic signs were
frequently found at the beginning of the disease when neuronal
loss was yet very rare (Broe et al., 2004). Moreover, in a different
study which focused on histological characteristics, astrogliosis
was found to be present at early stages of the disease (Kersaitis
et al., 2004). In later-stage cases, astrocytic apoptosis markers
increased while astrogliosis was found with less frequency (Broe
et al., 2004; Kersaitis et al., 2004). These findings support the
notion that glial pathology occurs at the very starting of the illness
besides being a major feature during the course of the disease.
Parkinson Disease
In an extensive research done in human brains, Braak et al.
(2003) demonstrated that α-synuclein deposition involves a wider
brain area than the one that becomes symptomatic and that these
symptoms appear at a later stage on the course of the disease,
once neurons become affected at a high percentage. Curiously,
the cells that do develop changes at early stages of intracellular
α-synuclein deposition are astrocytes. In animal models, the
accumulation of astrocytic cytoplasmatic α-synuclein eventually
leads not only to astrocytic dysfunction but also to microglia
activation through the release of cytokines and chemokines.
These changes, in turn, determine the injury and eventually the
non-cell autonomous killing of neurons (Halliday and Stevens,
2011).
In addition, several of the proteins codified by the altered
genes in autosomic recessive forms of hereditary PD (Parkin,
PINK-1, DJ-1), are mainly concentrated in astrocytes (McGeer
and McGeer, 2008; Halliday and Stevens, 2011).
Alzheimer Disease
In one of the only two transgenic animal models that mimic both
the plaque deposition and the neurofibrillary tangles observed
in humans (Oddo et al., 2003) it has been observed that the
early-term and start of the mid-term stages of the illness are
characterized by the presence of hippocampal astroglia atrophy
(6 months of age). This period is followed by the appearance
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of Aβ plaques and neurodegeneration in association with the
persistence of astrocyte atrophy as well as astrogliosis in the
periplaque area (Olabarria et al., 2010). Moreover, in the same
mouse model early astrocytic atrophy was also found in the
entorhinal cortex at 1 month of age (Yeh et al., 2011) and in
the prefrontal dorsolateral cortex since the 3rd month of age
(Kulijewicz-Nawrot et al., 2012), in both cases without later
periplaque astrogliosis and preceding neuronal dysfunction by
even broader lapses.
Acquired Neuropsychiatric Diseases
In several acquired neuropsychiatric disorders such as hepatic
encephalopathy, Wernicke encephalopathy and heavy metals
encephalopathy astrocytes are the primary affected cells
(Rönnbäck and Hansson, 1992; Hazell, 2009; Rama Rao
and Norenberg, 2014). Their dysfunction is believed to
determine neuronal injury and eventually death through
glutamate toxicity. Astrocytes are the only brain cells capable
of metabolizing ammonia through the enzyme glutamine
synthetase. However, the excessive concentration of ammonia in
hepatic encephalopathy determines an uncommon availability
of glutamate precursors as well as an increased production of
reactive oxygen and nitrogen species which ultimately lead to
astrocytic mitochondrial dysfunction (Rama Rao and Norenberg,
2014).
Amyotrophic Lateral Sclerosis
Several observations support the idea that there is an early if not
primary astrocytic damage in this disease (Sica, 2012).
To begin with, it was observed that transplantation of mutated
SOD 1 expressing glial progenitors, able to differentiate into
astrocytes, into the spinal cord of wild type rats induce motor
neurons degeneration and clinical symptoms in vivo (Papadeas
et al., 2011; Tong et al., 2013).
Furthermore, Rossi et al. (2008) employing the transgenic
mouse model expressing the human SOD1G93A, identified a
degenerative process involving a subset of astrocytes confined
to the microenvironment of the spinal motor neurons. More
importantly, the time-course of appearance of these cells was
at the 75th day of age, that is, before the loss of motor
cells. Moreover, the quoted astrocyte degeneration and its
consequences were experimentally slowed down by the injection
of 2-methyl-6-pyridine, a selective antagonist to the mGluR5
glutamate receptor. Therefore, glutamate toxicity seems to
have a major role in astrocyte and neuron degeneration in
mutant SOD1G93A mice. These findings are consistent with
the previously reported selective up-regulation of mGluR5 in
astrocytes in the ventral spinal cord of ALS patients (Aronica
et al., 2001).
Other notorious publication that has been referred to ever
since is Bruijn et al. (1997) description of findings in genetically
induced ALS mice. In this experimental study, transgenic
and control mice were sacrificed at different ages and their
CNS analyzed. They noted that the first pathological findings
were astrocytic cytoplasmic aggregates that were approximately
1 month later observed in neurons and which preceded the
clinical disease onset by 2.5 months.
Spinocerebellar Ataxia (SCA)
Custer et al. (2006) demonstrated that in the polyglutamine
disease SCA7, Purkinje cells undergo non-cell-autonomous
degeneration in transgenic animals. They generated mice
expressing ataxin-7 only in Bergmann glia (a specialized
type of cerebellum’s astrocytes in close contact with
Purkinje cells), which was sufficient to produce ataxia and
neurodegeneration. In a similar fashion, Garden et al. (2002)
also demonstrated that transgenic mice expressing ataxin-
7 with 92 glutamines repeats (92Q) in non-neural cells at
the cerebellum promoted Purkinje cells’ degeneration and
therefore developed a dramatic neurological phenotype
presenting as a gait ataxia and culminating in premature
death despite the absence of its expression in Purkinje
cells.
Huntington’s Disease (HD)
In animal mouse models it was observed that mice expressing
mutated Huntingtin (mhtt) in neurons show mild or no
neurological sings, while mice expressing mhtt only in
astrocytes have a reduced expression of astrocyte glutamate
transporters and end up developing neurological deficits and
an earlier neuronal death than when compared with control
transgenic or wild-type mice (Gu et al., 2005; Bradford et al.,
2009).
These observations are also supported by cultures results,
where co-culturing wild mice neurons with astrocytes that over-
express mhtt have shown that neurons undergo apoptosis, once
more suggesting that those astrocytes have a deleterious effect
onto normal neurons (Shin et al., 2005).
In humans, Faideau et al. (2010) observed reactive astrocytosis
in the dorsal striatum in grade 0 HD subjects, when no neuronal
damage is still apparent, with dorso-ventral striatum progression
through grade 4 specimens. Despite being only two 0 HD human
brain samples, we believe that these findings deserve at least
further investigation.
CONCLUSION
It has broadly been observed an early astrocytic dysfunction in
the PDDs of the CNS. In the present mini review, this concept
has been exemplified in CNS at its whole length: starting in
the spine or the brain stem in ALS patients, ascending to the
midbrain in PD, the cerebellum in SCA-7, the striatum in HD, the
hippocampus in AD, the prefrontal cortex in FTD and, finally,
compromising in a more subtle fashion the whole cortical gray
matter in SCZ.
We advocate that these observations obtained from different
degenerative pathologies, but mostly from experimental animal
studies, may be the trees from a forest characterized by primary
astrocytic dysfunction as the main process starting them.
We believe that in these particular pathologies, investigations
conducted on human brain samples are absolutely necessary to
confirm and expand the findings achieved in animal studies.
This is based on the fact that particularly in cognitive pathology,
anatomopathological findings do not necessary correlate with
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clinical symptoms (hence the actual disease) and that healthy
animals do not acquire the high mental functions later to be lost,
and therefore their analysis does not necessarily represent the
human reality.
As a non yet explored approach, were astrocytic dysfunction
to be of a diffuse fashion, the classically end-stage affected
brain areas could be the ones to harbor early astrocytic
pathology without neuron disease. Were astrocytic pathology
to be restricted to a focused cerebral region, early changes in
already symptomatic patients are unlikely to be studied although
Parkinson and Alzheimer’s disease may be the exceptions due to
their known sequence of progression.
We support the idea that a study with human samples focused
in the context of the different diseases so far mentioned might
allow to ascertain through detailed description characteristics
previously overlooked, thus obtaining hints of a paradigmatic
physiopathological process in which the astrocytes might be the
main players.
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